SciSparc’s 75% Owned NeuroThera Labs Files PCT Patent for MEAI-PEA Therapy
SciSparc’s majority-owned NeuroThera Labs published an international PCT patent application for its MEAI-PEA combination therapy targeting obesity and metabolic dysfunction-associated steatotic liver disease, with potential as a non-hallucinogenic neuroplastogen. The global weight loss drug market was valued at $37 billion in 2025 and is forecast to reach $226 billion by 2035.
1. Patent Publication and Collaboration
SciSparc’s subsidiary NeuroThera Labs, in which SciSparc holds approximately 75%, filed an international patent application under the PCT for a novel MEAI-PEA combination therapy. The collaboration with Clearmind Medicine brings together MEAI’s platform and Palmitoylethanolamide to develop a non-hallucinogenic neuroplastogen for obesity and fatty liver disease.
2. Market Potential and Strategic Impact
The global weight loss drugs market reached $37 billion in 2025 and is projected to expand to $226 billion by 2035, driven by rising obesity rates and demand for alternatives to GLP-1 agonists. This therapy aims to capture market share by offering a safer, more cost-effective option for treating obesity and MASLD.